Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection

Yasunori Sawayama, Jun Hayashi, Yasunobu Kawakami, Norihiro Furusyo, Iwao Ariyama, Yasuhiro Kishihara, Kumiko Ueno, Seizaburo Kashiwagi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To determine the role of serum soluble interleukin-2 receptor (sIL-2R) in chronic hepatitis B virus (HBV) infection, the level of serum sIL-2R was measured in sera of 105 patients with chronic HBV infection and in 21 healthy controls, using enzyme-linked immunosorbent assay. Serum sIL-2R levels were significantly higher in Chronic HBV-infected patients with chronic hepatitis (508 ± 310 units/ml) and liver cirrhosis (543 ± 283 units/ml) than in healthy controls (331 ± 106 units/ml, P < 0.05). Moreover, serum sIL-2R levels were significantly higher in patients with chronic hepatitis or liver cirrhosis than in asymptomatic HBV carriers (341 ± 150 units/ml, P < 0.01). There was no difference in serum sIL-2R levels between asymptomatic HBV carriers and healthy controls or between patients With chronic hepatitis and liver cirrhosis. A significant relationship was found between serum sIL-2R and ALT levels (P < 0.05) in patients with chronic HBV infection, although there was no correlation between sID-2R and HBV DNA levels. Serum sIL-2R levels in most patients decreased to the same level as asymptomatic HBV carriers and healthy controls at 48 weeks after the end of treatment, and serum ALT and HBV DNA levels were decreased to within the normal range at 96 weeks. Thus, serum sIL-2R levels indicate the degree Of liver damage among patients with Chronic HBV infection. The serum sIL-2R levels one year after interferon administration may be a useful marker of determined at the effectiveness by this treatment.

Original languageEnglish
Pages (from-to)163-169
Number of pages7
JournalDigestive Diseases and Sciences
Volume44
Issue number1
DOIs
Publication statusPublished - 1999

Fingerprint

Interleukin-2 Receptors
Chronic Hepatitis B
Virus Diseases
Hepatitis B virus
Interferons
Serum
Chronic Hepatitis
Therapeutics
Liver Cirrhosis
DNA
Reference Values
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection. / Sawayama, Yasunori; Hayashi, Jun; Kawakami, Yasunobu; Furusyo, Norihiro; Ariyama, Iwao; Kishihara, Yasuhiro; Ueno, Kumiko; Kashiwagi, Seizaburo.

In: Digestive Diseases and Sciences, Vol. 44, No. 1, 1999, p. 163-169.

Research output: Contribution to journalArticle

Sawayama, Y, Hayashi, J, Kawakami, Y, Furusyo, N, Ariyama, I, Kishihara, Y, Ueno, K & Kashiwagi, S 1999, 'Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection', Digestive Diseases and Sciences, vol. 44, no. 1, pp. 163-169. https://doi.org/10.1023/A:1026674705459
Sawayama, Yasunori ; Hayashi, Jun ; Kawakami, Yasunobu ; Furusyo, Norihiro ; Ariyama, Iwao ; Kishihara, Yasuhiro ; Ueno, Kumiko ; Kashiwagi, Seizaburo. / Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection. In: Digestive Diseases and Sciences. 1999 ; Vol. 44, No. 1. pp. 163-169.
@article{cc15f7d2b6eb458a99ed429cd166bc40,
title = "Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection",
abstract = "To determine the role of serum soluble interleukin-2 receptor (sIL-2R) in chronic hepatitis B virus (HBV) infection, the level of serum sIL-2R was measured in sera of 105 patients with chronic HBV infection and in 21 healthy controls, using enzyme-linked immunosorbent assay. Serum sIL-2R levels were significantly higher in Chronic HBV-infected patients with chronic hepatitis (508 ± 310 units/ml) and liver cirrhosis (543 ± 283 units/ml) than in healthy controls (331 ± 106 units/ml, P < 0.05). Moreover, serum sIL-2R levels were significantly higher in patients with chronic hepatitis or liver cirrhosis than in asymptomatic HBV carriers (341 ± 150 units/ml, P < 0.01). There was no difference in serum sIL-2R levels between asymptomatic HBV carriers and healthy controls or between patients With chronic hepatitis and liver cirrhosis. A significant relationship was found between serum sIL-2R and ALT levels (P < 0.05) in patients with chronic HBV infection, although there was no correlation between sID-2R and HBV DNA levels. Serum sIL-2R levels in most patients decreased to the same level as asymptomatic HBV carriers and healthy controls at 48 weeks after the end of treatment, and serum ALT and HBV DNA levels were decreased to within the normal range at 96 weeks. Thus, serum sIL-2R levels indicate the degree Of liver damage among patients with Chronic HBV infection. The serum sIL-2R levels one year after interferon administration may be a useful marker of determined at the effectiveness by this treatment.",
author = "Yasunori Sawayama and Jun Hayashi and Yasunobu Kawakami and Norihiro Furusyo and Iwao Ariyama and Yasuhiro Kishihara and Kumiko Ueno and Seizaburo Kashiwagi",
year = "1999",
doi = "10.1023/A:1026674705459",
language = "English",
volume = "44",
pages = "163--169",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection

AU - Sawayama, Yasunori

AU - Hayashi, Jun

AU - Kawakami, Yasunobu

AU - Furusyo, Norihiro

AU - Ariyama, Iwao

AU - Kishihara, Yasuhiro

AU - Ueno, Kumiko

AU - Kashiwagi, Seizaburo

PY - 1999

Y1 - 1999

N2 - To determine the role of serum soluble interleukin-2 receptor (sIL-2R) in chronic hepatitis B virus (HBV) infection, the level of serum sIL-2R was measured in sera of 105 patients with chronic HBV infection and in 21 healthy controls, using enzyme-linked immunosorbent assay. Serum sIL-2R levels were significantly higher in Chronic HBV-infected patients with chronic hepatitis (508 ± 310 units/ml) and liver cirrhosis (543 ± 283 units/ml) than in healthy controls (331 ± 106 units/ml, P < 0.05). Moreover, serum sIL-2R levels were significantly higher in patients with chronic hepatitis or liver cirrhosis than in asymptomatic HBV carriers (341 ± 150 units/ml, P < 0.01). There was no difference in serum sIL-2R levels between asymptomatic HBV carriers and healthy controls or between patients With chronic hepatitis and liver cirrhosis. A significant relationship was found between serum sIL-2R and ALT levels (P < 0.05) in patients with chronic HBV infection, although there was no correlation between sID-2R and HBV DNA levels. Serum sIL-2R levels in most patients decreased to the same level as asymptomatic HBV carriers and healthy controls at 48 weeks after the end of treatment, and serum ALT and HBV DNA levels were decreased to within the normal range at 96 weeks. Thus, serum sIL-2R levels indicate the degree Of liver damage among patients with Chronic HBV infection. The serum sIL-2R levels one year after interferon administration may be a useful marker of determined at the effectiveness by this treatment.

AB - To determine the role of serum soluble interleukin-2 receptor (sIL-2R) in chronic hepatitis B virus (HBV) infection, the level of serum sIL-2R was measured in sera of 105 patients with chronic HBV infection and in 21 healthy controls, using enzyme-linked immunosorbent assay. Serum sIL-2R levels were significantly higher in Chronic HBV-infected patients with chronic hepatitis (508 ± 310 units/ml) and liver cirrhosis (543 ± 283 units/ml) than in healthy controls (331 ± 106 units/ml, P < 0.05). Moreover, serum sIL-2R levels were significantly higher in patients with chronic hepatitis or liver cirrhosis than in asymptomatic HBV carriers (341 ± 150 units/ml, P < 0.01). There was no difference in serum sIL-2R levels between asymptomatic HBV carriers and healthy controls or between patients With chronic hepatitis and liver cirrhosis. A significant relationship was found between serum sIL-2R and ALT levels (P < 0.05) in patients with chronic HBV infection, although there was no correlation between sID-2R and HBV DNA levels. Serum sIL-2R levels in most patients decreased to the same level as asymptomatic HBV carriers and healthy controls at 48 weeks after the end of treatment, and serum ALT and HBV DNA levels were decreased to within the normal range at 96 weeks. Thus, serum sIL-2R levels indicate the degree Of liver damage among patients with Chronic HBV infection. The serum sIL-2R levels one year after interferon administration may be a useful marker of determined at the effectiveness by this treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032897664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032897664&partnerID=8YFLogxK

U2 - 10.1023/A:1026674705459

DO - 10.1023/A:1026674705459

M3 - Article

C2 - 9952238

AN - SCOPUS:0032897664

VL - 44

SP - 163

EP - 169

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 1

ER -